← All trials
NCT05946486
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2023
- Primary completion
- Jan 15, 2026
- Completion date
- Dec 15, 2026
- First posted
- Jul 14, 2023
- Last posted
- Jul 14, 2023
- Enrollment
- 174
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BordeauxLead sponsor
- University of BordeauxOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.